2020, Number 06
<< Back Next >>
Revista Médica Sinergia 2020; 5 (06)
Update on Kawasaki disease in pediatric population
Mejía AC, Sandí ON, Salazar CN
Language: Spanish
References: 15
Page: 1-11
PDF size: 156.05 Kb.
ABSTRACT
Kawasaki disease, also known as mucocutaneous lymphatic syndrome, from unknown etiology, and characterized by an acute vasculitis which
affects predominantly medium-sized arteries, and has a predisposition to
form coronary artery aneurysms. It is described as a febrile illness in
children under five years old with a genetic predisposition in Asian
countries, such as Japan. Being a rare disease, the diagnosis is clinical so,
no complementary studies are needed to confirm it and it can be followed
with important sequelae if treatment is not started early. The main treatment
is based in intravenous immunoglobulin and acetylsalicylic acid, both used
with the purpose of reducing the duration of the fever and inflammation, in
addition to prevent coronary artery aneurysms.
REFERENCES
Kim GB. Reality of Kawasaki disease epidemiology. Korean J Pediatr. 2019; 62(8)292-296. https://doi.org/10.3345/kjp.2019.00157
Lee DS. Does any specific infection cause Kawasaki disease? Korean J Pediatr. 2019;62(6): 213-214. https://doi.org/10.3345/kjp.2019.00129
Singh S, Jindal AK, Pilania RK. Diagnosis of Kawasaki disease. International Journal of Rheumatic Diseases. 2018;21(1):36-44. https://doi.org/10.1111/1756-185X.13224
Sosa T, Browner L, Divanovic A. Diagnosis and Management of Kawasaki. JAMA Network Clinical Guidline Synopsis. 2019;173(3):278-279. https://doi.org/10.1001/jamapediatrics.2018.3307
Kuo HC. Preventing coronary artery lesions in Kawasaki disease. Biomedical Journal XXX. 2017; 40(3):141-146. https://doi.org/10.1097/MCA.0000000000000792
Ramphul K, Mejias SG, Joynauth J. Kawasaki disease among children in the United States. Reumatología. 2019;57(4): 253-254. https://doi.org/10.5114/reum.2019.87618
Son MBF, Newburger JW. Kawasaki Disease. Pediatrics in Review. 2018;39(2):78-92. https://doi.org/10.1542/pir.2016-0182
Fuller MG. Kawasaki Disease in Infancy. Advanced Emergency Nursing Journal. 2019;41(3): 222-228. https://doi.org/10.1097/TME.0000000000000253
Pasma H, Honkila M, Pokka T, Renko M, Salo E, Tapiainen T. Epidemiology of Kawasaki disease before and after universal Bacille Calmette-Guérin vaccination program was discontinued. Acta Pediátrica Wiley. 2019; 00: 1-5. https://doi.org/10.1111/apa.15012
Marrani E, Burns JC, Cimaz R. How Sould We Classify Kawasaki Disease? Frontiers in Immunology. 2018; 9:2974. https://doi.org/10.3389/fimmu.2018.02974
Shulman St, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nature Reviews Rheumatology. 2015; 11, 475-482. https://doi.org/10.1038/nrrheum.2015.54
Moreno MA. Summarizing What Has Been Learned About Kawasaki Disease. JAMA Pediatrics Patient Page. 2016;170(11):1124. https://doi.org/10.1177/0009922817729483
Jindal AK, Pilania RK, Prithvi A, Guleria S, Singh S. Kawasaki disease: characteristics, diagnosis and usual presentations. Expert Review of Clinical Immunology. 2019; 15(10):1089-1104. https://doi.org/10.1080/1744666X.2019.1659726
Ishii M, Kato H. History and Future of Treatment for Acute Stage Kawasaki Disease. Korean Circulation Journal. 2020; 50(2):e9. https://doi.org/10.4070/kcj.2019.0290
Esposito S, Bianchini S, Dellepiane RM, Principi N. Vaccines and Kasawaki disease. Expert Review of Vaccines. 2016;15(3):417-24. https://doi.org/10.1586/14760584.2016.1128329
Full text